In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MedCenterDirect.com

This article was originally published in The Gray Sheet

Executive Summary

E-health procurement portal announces a $12 mil. round of venture financing from New Enterprise Associates. The company is looking to deploy its e-commerce platform to more than 2,000 health care facilities by year-end through exclusive contracts with providers HealthSouth and the National Association of Community Health Centers. The company registered for a $131 mil. initial public offering on March 21 (1"The Gray Sheet" April 17, p. 12)

You may also be interested in...



Medcenterdirect.com E-Commerce B2B Pilot At NACHC Begins April 14

A pilot program which commenced April 14 at seven National Association of Community Health Centers (NACHC) member locations across the U.S. will evaluate medcenterdirect.com's online business-to-business e-commerce marketplace for the purchase and sale of medical and non-medical products, supplies and equipment used by alternate site, hospital and other healthcare providers.

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 
UsernamePublicRestriction

Register

MT013696

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel